Asia FX muted, dollar fragile as CPI data boosts Sept rate cut bets
BridgeBio Pharma emphasizes the potential for serum TTR levels to serve as a prognostic biomarker in ATTR-CM, aiding in treatment decisions and patient care. The company, which specializes in genetic diseases, views these findings as a significant addition to the body of evidence supporting the efficacy of acoramidis in treating ATTR-CM. While currently operating at a negative EBITDA of $662.65 million, the company has demonstrated strong market performance with a 50.13% price increase over the past six months. InvestingPro subscribers have access to over 30 additional financial metrics and insights about BridgeBio’s financial health and market position. While currently operating at a negative EBITDA of $662.65 million, the company has demonstrated strong market performance with a 50.13% price increase over the past six months. InvestingPro subscribers have access to over 30 additional financial metrics and insights about BridgeBio’s financial health and market position.
ATTR-CM is a condition characterized by the buildup of amyloid fibrils in the heart, leading to progressive heart failure and potentially death. Acoramidis, a selective TTR stabilizer, has been shown to increase serum TTR levels rapidly within 28 days of treatment initiation, a change that is sustained over 30 months. This increase is linked to a reduction in all-cause mortality, independent of other risk factors.
BridgeBio Pharma emphasizes the potential for serum TTR levels to serve as a prognostic biomarker in ATTR-CM, aiding in treatment decisions and patient care. The company, which specializes in genetic diseases, views these findings as a significant addition to the body of evidence supporting the efficacy of acoramidis in treating ATTR-CM. While currently operating at a negative EBITDA of $662.65 million, the company has demonstrated strong market performance with a 50.13% price increase over the past six months. InvestingPro subscribers have access to over 30 additional financial metrics and insights about BridgeBio’s financial health and market position.
Further analysis from the open-label extension data at Month 42 showed that acoramidis led to statistically significant reductions in both all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH). These results emphasize the importance of early and ongoing treatment with acoramidis for achieving better clinical outcomes.
The U.S. FDA has approved acoramidis under the brand name Attruby™, and it is also approved in Europe, Japan, and the UK as BEYONTTRA®. The approvals highlight the drug’s ability to stabilize TTR nearly completely.
BridgeBio Pharma emphasizes the potential for serum TTR levels to serve as a prognostic biomarker in ATTR-CM, aiding in treatment decisions and patient care. The company, which specializes in genetic diseases, views these findings as a significant addition to the body of evidence supporting the efficacy of acoramidis in treating ATTR-CM.
The ATTRibute-CM study’s results may influence clinical practice by establishing early and sustained increases in serum TTR as a potential biomarker for ATTR-CM, potentially guiding treatment choices and improving patient outcomes. This information is based on a press release statement from BridgeBio Pharma, Inc.
In other recent news, BridgeBio Pharma reported a strong financial performance for the first quarter of 2025, with total revenues reaching $116.6 million. This impressive figure was driven by the successful launch of their product Atruvy, which generated $36.7 million in net revenue, significantly exceeding analysts’ expectations. The company also received a positive outlook from Scotiabank, where analyst Greg Harrison raised the stock target to $55, citing strong sales performance of Atruvy for transthyretin amyloid cardiomyopathy (ATTR-CM).
BridgeBio is also making strides in clinical research, as they have initiated dosing in the ACT-EARLY trial, a study aimed at preventing transthyretin amyloid disease (ATTR) in asymptomatic carriers. The trial seeks to enroll approximately 600 participants and is considered a landmark study in the prevention of this genetic disease.
Additionally, BridgeBio ended the quarter with $540.6 million in cash and cash equivalents, positioning the company well for continued investment in its pipeline. The company is preparing for three Phase 3 clinical readouts within the next year, which could further impact its growth trajectory.
These developments highlight BridgeBio’s strategic focus on expanding its market presence and addressing unmet needs in genetic diseases. The company’s efforts are supported by a robust financial foundation and a commitment to advancing its clinical pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.